Literature DB >> 19295502

Metabolic abnormalities are present in adults with elevated serum cystatin C.

Paul Muntner1, Suma Vupputuri, Josef Coresh, Jaime Uribarri, Caroline S Fox.   

Abstract

Although metabolic anomalies are often seen in advanced chronic kidney disease (CKD), their presence in more mild states is unknown. We studied 6722 participants in the Third National Health and Nutrition Examination Survey, dividing them into three mutually exclusive groups consisting of those having a normal or mildly reduced estimated glomerular filtration rate (eGFR) (Modification of Diet in Renal Disease (MDRD) formula), those with normal or elevated serum cystatin C, and those with clinically relevant moderate or severely reduced eGFR (stage 3 or 4 of CKD). The prevalence of several metabolic abnormalities associated with moderate to advanced CKD was determined after standardization for age, race-ethnicity, and gender. In the absence of stage 3 or 4 CKD, patients with elevated serum cystatin C had a higher prevalence of low hemoglobin and elevated uric acid, homocysteine, phosphorus, fibrinogen, and C-reactive protein than patients with a normal serum cystatin C. Our results show that in adults with normal or mildly reduced eGFR, elevated serum cystatin C is associated with an increased prevalence of metabolic abnormalities traditionally found in moderate or severe CKD. Elevated serum cystatin C may identify patients with 'preclinical' kidney disease not detected by traditional serum creatinine measurements.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19295502      PMCID: PMC3049931          DOI: 10.1038/ki.2009.76

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  31 in total

Review 1.  Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker.

Authors:  Margaret Sullivan Pepe; Holly Janes; Gary Longton; Wendy Leisenring; Polly Newcomb
Journal:  Am J Epidemiol       Date:  2004-05-01       Impact factor: 4.897

2.  Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients.

Authors:  N Cimerman; P M Brguljan; M Krasovec; S Suskovic; J Kos
Journal:  Clin Chim Acta       Date:  2000-10       Impact factor: 3.786

3.  Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study.

Authors:  A G Bostom; D Shemin; P Verhoef; M R Nadeau; P F Jacques; J Selhub; L Dworkin; I H Rosenberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-11       Impact factor: 8.311

4.  Mortality risk stratification in chronic kidney disease: one size for all ages?

Authors:  Ann M O'Hare; Daniel Bertenthal; Kenneth E Covinsky; C Seth Landefeld; Saunak Sen; Kala Mehta; Michael A Steinman; Ann Borzecki; Louise C Walter
Journal:  J Am Soc Nephrol       Date:  2006-02-01       Impact factor: 10.121

Review 5.  Cystatin C: an improved estimator of glomerular filtration rate?

Authors:  Omar F Laterza; Christopher P Price; Mitchell G Scott
Journal:  Clin Chem       Date:  2002-05       Impact factor: 8.327

6.  Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate.

Authors:  Josef Coresh; Brad C Astor; Geraldine McQuillan; John Kusek; Tom Greene; Frederick Van Lente; Andrew S Levey
Journal:  Am J Kidney Dis       Date:  2002-05       Impact factor: 8.860

7.  Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement.

Authors:  Eric L Knight; Jacobien C Verhave; Donna Spiegelman; Hans L Hillege; Dick de Zeeuw; Gary C Curhan; Paul E de Jong
Journal:  Kidney Int       Date:  2004-04       Impact factor: 10.612

8.  Serum cystatin C is sensitive to small changes in thyroid function.

Authors:  Peter Wiesli; Beat Schwegler; Giatgen A Spinas; Christoph Schmid
Journal:  Clin Chim Acta       Date:  2003-12       Impact factor: 3.786

9.  Prevalence of acidosis and inflammation and their association with low serum albumin in chronic kidney disease.

Authors:  Joseph A Eustace; Brad Astor; Paul M Muntner; T Alp Ikizler; Josef Coresh
Journal:  Kidney Int       Date:  2004-03       Impact factor: 10.612

10.  Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition.

Authors:  Yongmei Liu; Josef Coresh; Joseph A Eustace; J Craig Longenecker; Bernard Jaar; Nancy E Fink; Russell P Tracy; Neil R Powe; Michael J Klag
Journal:  JAMA       Date:  2004-01-28       Impact factor: 56.272

View more
  9 in total

1.  A multi-marker approach to predict incident CKD and microalbuminuria.

Authors:  Caroline S Fox; Philimon Gona; Martin G Larson; Jacob Selhub; Geoffrey Tofler; Shih-Jen Hwang; James B Meigs; Daniel Levy; Thomas J Wang; Paul F Jacques; Emelia J Benjamin; Ramachandran S Vasan
Journal:  J Am Soc Nephrol       Date:  2010-10-21       Impact factor: 10.121

2.  Reference intervals and factors contributing to serum cystatin C levels in a Chinese population.

Authors:  Dong-Dong Li; Meng-Na Zou; Xin Hu; Mei Zhang; Cheng-Yao Jia; Chuan-Min Tao; Lan-Lan Wang; Bin-Wu Ying
Journal:  J Clin Lab Anal       Date:  2012-02       Impact factor: 2.352

3.  Lower urinary connective tissue growth factor levels and incident CKD stage 3 in the general population.

Authors:  Conall M O'Seaghdha; Shih-Jen Hwang; Nrupen A Bhavsar; Anna Köttgen; Josef Coresh; Brad C Astor; Caroline S Fox
Journal:  Am J Kidney Dis       Date:  2011-02-03       Impact factor: 8.860

4.  Serum phosphorus predicts incident chronic kidney disease and end-stage renal disease.

Authors:  Conall M O'Seaghdha; Shih-Jen Hwang; Paul Muntner; Michal L Melamed; Caroline S Fox
Journal:  Nephrol Dial Transplant       Date:  2011-02-03       Impact factor: 5.992

5.  Performance of a genetic risk score for CKD stage 3 in the general population.

Authors:  Conall M O'Seaghdha; Qiong Yang; Hongsheng Wu; Shih-Jen Hwang; Caroline S Fox
Journal:  Am J Kidney Dis       Date:  2011-10-13       Impact factor: 8.860

6.  Prevalence of proteinuria and elevated serum cystatin C among HIV-Infected Adolescents in the Reaching for Excellence in Adolescent Care and Health (REACH) study.

Authors:  Kristal J Aaron; Mirjam-Colette Kempf; Robert H Christenson; Craig M Wilson; Paul Muntner; Sadeep Shrestha
Journal:  J Acquir Immune Defic Syndr       Date:  2012-12-01       Impact factor: 3.731

7.  Elevated galectin-3 precedes the development of CKD.

Authors:  Conall M O'Seaghdha; Shih-Jen Hwang; Jennifer E Ho; Ramachandran S Vasan; Daniel Levy; Caroline S Fox
Journal:  J Am Soc Nephrol       Date:  2013-06-13       Impact factor: 10.121

8.  Mineral metabolism and outcomes in chronic kidney disease stage 2-4 patients.

Authors:  Kamonwan Chartsrisak; Kotcharat Vipattawat; Montira Assanatham; Arkom Nongnuch; Atiporn Ingsathit; Somnuek Domrongkitchaiporn; Vasant Sumethkul; Sinee Distha-Banchong
Journal:  BMC Nephrol       Date:  2013-01-16       Impact factor: 2.388

9.  Development of a Competitive Cystatin C-Specific Bioassay Suitable for Repetitive Measurements.

Authors:  Tatjana Damm; Holger Spiegel; Stefan Barth; Rainer Fischer; Joerg Naehring
Journal:  PLoS One       Date:  2016-01-22       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.